The efficacy of different biomarkers and endpoints to refine referrals for suspected prostate cancer: the TARGET study (Tiered integrAted tests for eaRly diaGnosis of clinically significant ProstatE Tumours)
Incorporating phi or PSAd can refine and tier who is referred for tertiary imaging and/or biopsy after a raised PSA test. Incremental value however varied depending on the definition of clinical significance and was particularly useful when composite prognostic endpoints are used.
Authors
- Vincent J. Gnanapragasam (ORCID: https://orcid.org/0000-0003-4722-4207)
- Kenneth Muir (ORCID: https://orcid.org/0000-0001-6429-988X)
- Artitaya Lophatananon
Institutions
- University of Cambridge (GB)
- Manchester Academic Health Science Centre (GB)
- University of Manchester (GB)
- Addenbrooke's Hospital (GB)
Publication Details
- Journal
- BMC Medicine
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1186/s12916-024-03667-7
- Citations
- 3
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Oregon Health and Science University
- Cancer Research UK
- National Institute for Health and Care Research
- Department of Health and Social Care
- University College London
- Manchester Biomedical Research Centre
- Knight Cancer Institute, Oregon Health and Science University
- NIHR Cambridge Biomedical Research Centre